Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Details for Patent: 8,759,316

« Back to Dashboard

Which drugs does patent 8,759,316 protect, and when does it expire?

Patent 8,759,316 protects KENGREAL and is included in one NDA.

This patent has thirty patent family members in eleven countries.

Summary for Patent: 8,759,316

Title:Maintenance of platelet inhibition during antiplatelet therapy
Abstract: A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding.
Inventor(s): Ruderman Chen; Lisa (Rye, NY), Skerjanec; Simona (Basel, CH), Bell; Dawn (Morristown, NJ), Prats; Jayne (Carlisle, MA), Todd; Meredith (Hoboken, NJ), Arculus-Meanwell; Clive Arthur (Bernardsville, NJ), Mould; Diane (Fort Meyers, FL)
Assignee: The Medicines Company (Parsippany, NJ)
Application Number:13/931,384
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Chiesi Usa Inc
KENGREAL
cangrelor
POWDER;IV (INFUSION)204958-001Jun 22, 2015RXYesYes8,759,316► Subscribe P2Y12 PLATELET INHIBITOR FOR USE AS ADJUNCT TO PERCUTANEOUS CORONARY INTERVENTIONTO REDUCE RISK OF VARIOUS DISEASES/CONDITIONS IN PATIENTS NOT TREATED WITH A P2Y12 PLATELET INHIBITOR AND NOT GIVEN A GLYCOPROTEIN IIB/IIIA INHIBITOR
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,759,316

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,871,736Maintenance of platelet inhibition during antiplatelet therapy► Subscribe
9,320,754Maintenance of platelet inhibition during antiplatelet therapy► Subscribe
9,427,448Methods of treating, reducing the incidence of, and/or preventing ischemic events► Subscribe
8,716,261Maintenance of platelet inhibition during antiplatelet therapy► Subscribe
8,680,052Methods of treating, reducing the incidence of, and/or preventing ischemic events► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,759,316

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2009246396► Subscribe
Australia2010319612► Subscribe
Australia2012295343► Subscribe
Australia2013381855► Subscribe
Australia2016204562► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc